Perimenopause biology
Perimenopause begins when ovarian follicle recruitment starts to fail — FSH rises as the pituitary attempts to stimulate progressively fewer responsive follicles. Oestrogen levels are highly variable (not simply declining — they can be normal, high, or low across different menstrual cycles) before eventually establishing the low post-menopausal baseline.
- Vasomotor symptoms (hot flushes):Occur in 75% of perimenopausal women. Caused by narrowing of the thermoregulatory zone in the hypothalamus (mediated by changes in kisspeptin/neurokinin B signalling as oestrogen declines). Brief episodes of vasodilation and sweating. IL-6 and TNF-α from central neuroinflammation may modulate the threshold.
- Irregular heavy bleeding:Anovulatory cycles in perimenopause lack progesterone to oppose oestrogen's endometrial stimulation — causing irregular, often heavy periods before eventual cessation. This period is the highest risk for iron deficiency in the reproductive lifespan.
- Emerging cardiovascular risk:Oestrogen protects vascular endothelium by maintaining NO bioavailability and suppressing ICAM-1/VCAM-1 expression. As oestrogen declines, NOX2-driven endothelial oxidative stress increases, contributing to the cardiovascular risk acceleration seen post-menopause.
- Bone loss:Begins 2–3 years before the final period; accelerates significantly in the first 5 years post-menopause. Calcium and vitamin D are primary interventions; spirulina provides calcium (120–170 mg/10 g) but not vitamin D.
Iron status in perimenopause
Iron management during perimenopause requires careful attention to the specific phase:
- Heavy perimenopausal bleeding:Iron deficiency risk is highest. Check ferritin every 6–12 months if periods are heavy or prolonged. Spirulina iron with vitamin C is appropriate if ferritin <50 µg/L; ferrous bisglycinate is preferred for moderate-severe deficiency.
- After menopause (periods ceased):Iron loss from menstruation stops. Post-menopausal women no longer need the same iron intake as premenopausal. Ferritin can rise. If ferritin >200 µg/L post-menopause: spirulina iron is not indicated; investigate for haemochromatosis or other cause.
GLA and vasomotor symptoms
GLA from spirulina (0.5–1.5 g per 10 g) converts to DGLA, which reduces production of the pro-inflammatory prostaglandin E2 (PGE2):
- PGE2 modulates thermoregulatory responses in the hypothalamus — elevated PGE2 lowers the thermoneutral zone and may amplify the hot flush response
- Evening primrose oil (2–4 g/day GLA) has modest evidence for hot flush frequency reduction in perimenopausal women. Spirulina at 10 g/day provides 0.5–1.5 g GLA — lower than therapeutic EPO doses but directionally relevant
- The evidence for GLA specifically reducing vasomotor symptoms is modest and not definitive. Honest expectation: a small contribution to inflammatory modulation of hot flushes, not elimination.
Phycocyanobilin and cardiovascular protection
- The post-menopausal acceleration of cardiovascular risk involves exactly the NOX2-driven endothelial oxidative stress that phycocyanobilin inhibits. NO depletion from NOX2 superoxide — previously protected by oestrogen — causes endothelial dysfunction and initiates atherogenesis.
- Spirulina RCTs in post-menopausal women (Ryu 2008, Choi 2008) showed reduced LDL, increased HDL, and improved cholesterol profiles at 8 g/day — consistent with the vascular mechanism.
No phytoestrogenic activity
This must be stated explicitly: spirulina does not contain phytoestrogens (isoflavones, lignans, coumestans) in meaningful amounts. It does not mimic oestrogen, does not bind oestrogen receptors, and does not substitute for hormone replacement therapy. For moderate-to-severe perimenopause symptoms, HRT (hormone replacement therapy) remains the most evidence-based intervention and should be discussed with a GP or gynaecologist.
Practical guidance
- Check ferritin every 6–12 months during perimenopause if periods are heavy — adjust spirulina iron use based on result
- 5–10 g/day appropriate during perimenopause for cardiovascular, anti-inflammatory, and nutritional support
- GLA contribution at this dose: 0.25–1.5 g/day — a modest vasomotor symptom support component; not equivalent to EPO therapy
- Calcium from spirulina: 60–170 mg/10 g contributes to bone protection alongside diet — vitamin D supplementation (10 µg/day UK guidance) is separate and still required
- Discuss all supplements with GP when considering perimenopause management — particularly if HRT is being considered, spirulina has no known interaction with HRT preparations